Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
J Neurochem. 2013 Sep;126(6):781-91. doi: 10.1111/jnc.12329. Epub 2013 Jul 1.
Frontotemporal lobar degeneration (FTLD) is the second leading cause of dementia in individuals under age 65. In many patients, the predominant pathology includes neuronal cytoplasmic or intranuclear inclusions of ubiquitinated TAR DNA binding protein 43 (FTLD-TDP). Recently, a genome-wide association study identified the first FTLD-TDP genetic risk factor, in which variants in and around the TMEM106B gene (top SNP rs1990622) were significantly associated with FTLD-TDP risk. Intriguingly, the most significant association was in FTLD-TDP patients carrying progranulin (GRN) mutations. Here, we investigated to what extent the coding variant, rs3173615 (p.T185S) in linkage disequilibrium with rs1990622, affects progranulin protein (PGRN) biology and transmembrane protein 106 B (TMEM106B) regulation. First, we confirmed the association of TMEM106B variants with FTLD-TDP in a new cohort of GRN mutation carriers. We next generated and characterized a TMEM106B-specific antibody for investigation of this protein. Enzyme-linked immunoassay analysis of progranulin protein levels showed similar effects upon T185 and S185 TMEM106B over-expression. However, over-expression of T185 consistently led to higher TMEM106B protein levels than S185. Cycloheximide treatment experiments revealed that S185 degrades faster than T185 TMEM106B, potentially due to differences in N-glycosylation at residue N183. Together, our results provide a potential mechanism by which TMEM106B variants lead to differences in FTLD-TDP risk. We studied the p.T185S TMEM106B genetic variant previously implicated in frontotemporal dementia with TAR DNA binding protein 43 pathology caused by progranulin mutations. Our cell culture studies provide evidence that the protective S185 isoform is degraded more rapidly than T185 TMEM106B, potentially due to differences in glycosylation. These findings suggest that low TMEM106B levels might protect against FTLD-TDP in these patients.
额颞叶变性(FTLD)是 65 岁以下人群第二大常见痴呆病因。在许多患者中,主要的病理学表现包括神经元细胞质或核内泛素化 TAR DNA 结合蛋白 43(FTLD-TDP)包涵体。最近,一项全基因组关联研究确定了第一个 FTLD-TDP 遗传风险因素,其中 TMEM106B 基因内和周围的变体(顶级 SNP rs1990622)与 FTLD-TDP 风险显著相关。有趣的是,最显著的关联是在携带颗粒蛋白前体(GRN)突变的 FTLD-TDP 患者中。在这里,我们研究了与 rs1990622 连锁不平衡的编码变体 rs3173615(p.T185S)在多大程度上影响颗粒蛋白(PGRN)生物学和跨膜蛋白 106B(TMEM106B)的调节。首先,我们在新的 GRN 突变携带者队列中证实了 TMEM106B 变体与 FTLD-TDP 的关联。接下来,我们生成并表征了一种 TMEM106B 特异性抗体用于该蛋白的研究。颗粒蛋白水平的酶联免疫吸附分析显示,T185 和 S185 TMEM106B 过表达时具有相似的效果。然而,过表达 T185 始终导致 TMEM106B 蛋白水平高于 S185。环已酰亚胺处理实验表明,S185 比 T185 TMEM106B 降解更快,这可能是由于残基 N183 的 N-糖基化差异所致。总之,我们的结果提供了一种潜在的机制,即 TMEM106B 变体导致 FTLD-TDP 风险的差异。我们研究了先前与颗粒蛋白突变引起的 TAR DNA 结合蛋白 43 病理学相关的额颞痴呆中涉及 p.T185S TMEM106B 遗传变体,我们的细胞培养研究提供了证据表明,保护性 S185 同工型比 T185 TMEM106B 降解更快,这可能是由于糖基化的差异。这些发现表明,在这些患者中,TMEM106B 水平较低可能有助于预防 FTLD-TDP。